REMINDER: Our user survey closes on Friday, please submit your responses here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Will never, ever understand why people turn philanthropic share advisers. Why is he wasting his time posting this rhubarb?
Pension funds look for stability & measured growth. I’m no financial expert but think you might be talking *******s.
Truth - Not sure how many times you can say Avacta are ‘bad’?
One of the largest investors into Avacta is pension funds... Yes, unfortunately this includes my pension fund... Yes, I was keen on Avacta some 7-8 years ago when there were bold claims of disruption. However, many of these claims have come by the wayside. I see a company divided, lacking focus and trying to excel in both diagnostics and therapeutics (each challenging enough on their own), over promising yet under delivers on nearly all occasions. It is literally a company which cannot get out of its own way. Perhaps its a technology issue, perhaps its a management issue, perhaps both. Regardless of my views derived from decades of experience in the biotech industry, until my pension fund withdraws completely I will be here. I will also happily eat my words should Avacta deliver, but I wont hold my breath.
That’s pretty embarrassing Daprophet. Did you treat yourself?
The contact us page I assume takes you to Avacta direct enquires, not distribution purchasing. Two very different markets and should have different contact forms, even if the distributor link takes you to an external site ie distributor
When shareholders provide the company with some useful advice and it's not only ignore but they don't even bother to reply it does become a little annoying.
I've emailed them four times now suggesting they put distributor details on their website so buyers know who to contact. I think on the Avacta product page it says contact your local distributor, common sense would tell me to put those details on the contact page or a hyperlink to the distributor landing page.
I understand lots of private investors are emailing the company and they are probably now ignoring most emails but it all about the purchasing user experience and Avacta have done nothing to improve it.
Avacta have done an exceptional job. To get an antigen test to market is in the current climate is a fantastic achievement. What worries me is the time frames used by some private investors.
This isn't a get rich quick scheme and there are more investors who fail. However, if you get beyond the negative and destructive criticism on this BB, you'll stand to make some money.
GLA
You’re essentially saying you have no faith in Affimers, or Avacta’s ability to market them. Suggest you should not be invested in a company that puts some much faith in Affimers.
TruthandTrust, you were unhappy in June 2020, 13 months later you post again, still unhappy
There is always a solution
Ps is anybody else getting strapons advertising below?
Ps is anybody getting strapons popping up below??
Could be targetted advertising Da Prophet?
Someone might be getting you pegged.
Top tip, he’s not on this board.
No, just you, the adverts are personalised based on your browsing. Awkward.
AS where are you!!
The door bells ringing but know one's home..
We are being left to rot in here..
What is our capacity now.. Where is the t&t with abdx? What is the expected future relationship with mologic and ghd now? Odx expects home approval before end of the month.. What about ours? Not buying anymore of this NDA nonsense anymore.. Or rofr.. Tut
Ps is anybody else getting strapons advertising below?
Ps is anybody getting strapons popping up below??
The first Moderna product to market was their covid vaccine, and they were founded in 2010. They were working on new biotech (mRNA tech), in a similar way to Avacta. If covid hadn't come along, Moderna still wouldn't have a product to market. CRISPR (founded 2013) and Intellia (founded 2014) Therapeutics still haven't brought a product to market, despite have ~10 billion dollar market cap each. This is biotech...it takes time, but the reward can be huge.
Avacta quick to RNS and slow to deliver. All of these deals and next to nothing to show for the nearly £100M invested... The lead Tx is not even an Affimer. The exclusive license for Anti-idiotypics for an extortionately low value (considering this was the only application that had any data - despite seeming background issues). Apologies, but we have all been around the block on this one and Im not holing my breath for the 'amazing breakthrough' we hear about on this board every 2 days...
bold statement with minimal data to back it up... a year+ on from announcing the test it seems everyone is still waiting.
Let’s hope Avct can get something to market in the way of Covid 19 testing, at least big Al and his team has at least a 100 years to get something approved!
https://apple.news/AjmCNPMpMRu-zxi0-E3F_2A
Yep no one is interested in affimers outside of Affidx, BAMS and ELISA tests.
https://avacta.com/diagnostic-licensing-deal-with-biokit/
https://avacta.com/affyxell-7-3-million-series-a-financing/
https://avacta.com/collaboration-agreement-with-bruker/
https://avacta.com/license-agreement-with-astrea-bioseparations/
https://avacta.com/avacta-and-lg-chem-life-sciences-expand-partnership/
https://avacta.com/expansion-of-partnership-with-daewoong-pharmaceutical-to-include-covid-19-neutralising-affimer-therapy/
https://avacta.com/collaboration-with-integumen-plc-for-detection-of-sars-cov-2-coronavirus-in-waste-water/
Far from unseating? You mean, they haven’t done in the 7 years to date.
They have delivered a Covid test, you’re right. But at the same time proven that Affimers outperform the Abs tool of choice.
yes, it seems that Leeds University is able to generate Affimer binders that work well in academic explorations. However, despite 7 years of efforts the Avacta team has generated a covid test and next to nothing else of commercial value (note how late to market the covid test was compared to many many other Ab based tests). It is clear that from a modality perspective Affimers MAY serve as a good Tx tool, however, for biomarkers Affimers are far from unseating Abs as the tool of choice.
... in so many ways.
https://www.sciencedirect.com/science/article/pii/S1046592820301182
"..affimers are promising antibody-replacement tools for protein biomarker assay development"
I know it's likely been posted, in fact I think I recall it, but at a time when the BB seems exhausted with nonsense, some reposted info is worth a reread to remind us of the probable huge IP about to unleash, whether within an independent Avacta or within a bigger Pharma corporate after a TO of Avacta. There has not been a single 'negative' post over the past 15 months which has reduced my conviction that Affimers will prevail (and I ignore here the other valuable IP owned by Avacta). I've been patient for 15 months, despite vaccine day in NOV 2020 and recent weeks, I can be patient for another 15 months, though I suspect that long won't be needed.